Biotechnology
Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment
PROVIDENCE, Rhode Island, Oct. 23, 2019 /PRNewswire/ -- Announced today, Chugai Pharmaceutical Co., Ltd. ("Chugai"), a member of the Roche Group, will extend the company's licensed access to theImmunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc. ...
2019-10-23 04:10
190
TissueCypher® Further Validated to Accurately Risk Stratify Barrett's Esophagus Patients With Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences
Data presented at ACG, UEGW illustrates the fourth independent validation of TissueCypher performance for risk stratifying non-dysplasticBarrett's esophagus (NDBE) patients; expands indication for testing low-grade dysplasia (LGD) PITTSBURGH, Oct. 23, 2019 /PRNewswire/ -- Cernostics, developer of...
2019-10-23 01:59
224
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
SUZHOU, China, Oct. 21, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today ...
2019-10-21 08:00
332
GELITA & Geltor Sign Letter of Intent to Commercialize First Animal-Free Biodesigned Collagen for Dietary Supplements, a Market with Huge Growth Potential
LAS VEGAS, Oct. 17, 2019 /PRNewswire/ -- In the halls of the SupplySide West (SSW) Expo, officials from both GELITA and Geltor signed a letter of intent for developing, producing and marketing the first ingestible animal-free collagen proteins – to be launched in late 2020. In this arrangement, G...
2019-10-17 18:32
376
MetGen Earns Acclaim from Frost & Sullivan for its Unique, Customized Enzyme Technologies, METNIN™ and ENZINE®
The technologies solve the industry's major pain points regarding the valorization of lignin, shorter technology development cycles, and customization of enzymes for different applications LONDON, Oct. 17, 2019 /PRNewswire/ -- Based on its recent analysis of the European industrial enzymes marke...
2019-10-17 15:00
326
Curiox Biosystems Achieves Commercialisation and Fund Raising Success in North Asia with the Support of Cornerstone Investor, ZIG Ventures
* CURIOX BIOSYSTEMS, is an A*STAR spinoff company, that develops bioinstrumentation solutions used in cell analysis and therapy for the pharmaceutical and biotech industries. The company has successfully penetrated theUSA, PRC, Korean and European markets and also secured a Series B funding of ...
2019-10-16 07:00
361
Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution
SEOUL, South Korea, and RIJSWIJK, The Netherlands, Oct. 15, 2019 /PRNewswire/ -- Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced today the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications...
2019-10-15 19:00
325
CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million
HONG KONG and NANJING, China, Oct. 9, 2019 /PRNewswire/ -- Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceu...
2019-10-09 20:58
472
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial
LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ -- - RESILIENT Protocol captures Encyclopedic information from tumors and uses Artificial Intelligence (AI) to optimize treatments; - Objective Response and Disease Control Comparable to or better than most Immunotherapy opti...
2019-10-09 17:56
773
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer
HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Han...
2019-10-08 08:00
455
Cross-industrial technologies make a splash in Asia Agri-Tech Expo in Taipei
TAIPEI, Oct. 5, 2019 /PRNewswire/ -- The Asia Agri-Tech Expo & Forum 2019 will take place at Taipei Nangang Exhibition Center Hall 1 fromOctober 31 to November 2. Organised by Informa Markets of Taiwan Office (UBM Taiwan), the tradeshow features innovative, eco-friendly and sustainable manufac...
2019-10-05 10:06
240
AGC Biologics Appoints New Site Head/General Manager of Copenhagen, Denmark Operations
Jeffrey D. Mowery Named Site Head/General Manager BOTHELL, Washington, Oct. 1, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment ofJeffery D. Mowery as Site Head/General Manager of theCopenhagen,...
2019-10-01 07:00
371
Interleukin 11 Identified as New Therapeutic Target for Idiopathic Pulmonary Fibrosis
* Idiopathic pulmonary fibrosis (IPF) is a severe and fatal disease that causes lung damage and scarring * Blocking a protein called interleukin-11 (IL11), which is abnormally high in the lungs of patients with IPF, can reverse lung fibrosis and scarring in preclinical studies * Enleofen Bi...
2019-09-30 15:00
206
Preclincal Results of Baoyuan's Next-Generation ROS1/NTRK Inhibitor AB-106 Published in Nature Communications
HANGZHOU, China, Sept. 25, 2019 /PRNewswire/ -- The preclinical results of AB-106 (original code: DS-6051b), an investigational next generation ROS1/NTRK dual inhibitor exclusively in-licensed by AnHeart Therapeutics, a wholly-owned subsidiary of Baoyuan Biopharmaceuticals Technology (Hangzhou) C...
2019-09-25 18:44
720
AGC Biologics Appoints New Site Head/General Manager of Chiba, Japan Operations
Naofumi Kagami Named Site Head/General Manager BOTHELL, Washington, Sept. 25, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment ofNaofumi Kagami as Site Head/General Manager of theChiba, Japan fa...
2019-09-25 01:42
1065
Supply Chain Digitization Creates New Revenue Opportunities in the Vaccine Market
High investment in adult immunization and innovations in DNA vaccines will rejuvenate the vaccines market, finds Frost & Sullivan SANTA CLARA, California, Sept. 24, 2019 /PRNewswire/ -- The need for improved immunogenicity, delivery technologies and reliable supply are driving the shift from the...
2019-09-24 23:28
1054
binx health Announces First Patients Benefiting From Single-Visit Test and Treatment for Chlamydia and Gonorrhea
binx FDA-cleared platform already impacting human health-poised to transform care for millions BOSTON, Sept. 23, 2019 /PRNewswire/ -- binx health, the pioneer in anywhere, anytime testing for women's health, today announced the first real-world use of the binxio platform, delivering same-visit d...
2019-09-23 20:30
898
2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors
SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced results from the microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumor cohort in the GEMSTONE-101 Phase Ib study of the Company's investigation...
2019-09-22 14:22
796
2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab
SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced preliminary results from the Phase Ia trial of the Company's anti-CTLA-4 antibody in an oral presentation at the 22nd Annual Meeting of the Chinese Society of Clinical Onco...
2019-09-22 13:39
943
Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 5, 2019
HONG KONG, Sept. 20, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 20...
2019-09-20 19:00
11307
Week's Top Stories
Most Reposted
ZTE and China Unicom win Best Network Intelligence Award at Broadband Awards 2019
[Picked up by 115 media titles]
2019-10-17 17:01
ZTE wins 5G Excellence Award at the SDN/NFV World Congress
[Picked up by 103 media titles]
2019-10-17 15:32
The Fullerton Hotel Sydney Debuts at No.1 Martin Place
[Picked up by 101 media titles]
2019-10-17 21:01Xinhua Silk Road: CEIS, Fitch Solutions jointly release report on opportunities in ASEAN under BRI
[Picked up by 96 media titles]
2019-10-17 09:10
Goodbaby Launched New Products Designed by Dutch Illustrator Rick Berkelmans in Celebration of its 30th Anniversary
[Picked up by 93 media titles]
2019-10-18 21:59
Most Read
Far East Hospitality Rethinks Luxury With the Launch of The Clan Hotel
2019-10-17 18:15
10414
Vinamilk impresses Chinese consumers with a wide range of high-quality dairy products
2019-10-17 10:45
8041
Infineon's New microcontroller optimized for automotive 77 GHz radar applications
2019-10-16 13:57
5363
